DDInter285 DDInter1676
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Capecitabine {u} (Compound) treats {v} (Disease) colon cancer
Capecitabine {u} (Compound) binds {v} (Gene) TYMS
Capecitabine {u} (Compound) upregulates {v} (Gene) MCOLN1
Capecitabine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Capecitabine {u} (Compound) causes {v} (Side Effect) Tonsillitis
Capecitabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Capecitabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Capecitabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metronidazole
Capecitabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Capecitabine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Capecitabine (Compound) treats colon cancer (Disease)
Capecitabine (Compound) binds TYMS (Gene)
Capecitabine (Compound) upregulates MCOLN1 (Gene)
Capecitabine (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class)
Capecitabine (Compound) causes Tonsillitis (Side Effect)
Capecitabine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin
Capecitabine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole
Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Capecitabine may lead to a major life threatening interaction when taken with Cladribine